CytoDyn’s stock forecast for 2025 is a topic of interest for investors as the company is developing a treatment for HIV. The stock has been volatile in recent years, but analysts are generally positive on the company’s long-term prospects.
There are several factors that could affect CytoDyn’s stock price in 2025. These include the results of clinical trials for the company’s HIV treatment, the regulatory environment for HIV drugs, and the overall performance of the stock market.
